Profusa reports Q2 2026 loss, advances G3 Vision Labs deal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. USO

Go back to Profusa reports Q2 2026 loss, advances G3 Vision Labs deal

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

August 20, 2026 8:30 AM EDT

Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock

Sufficient working capital obtained to fund operations for near term

PCAOB audited 2024 and 2025 financials of G3 and Subsidiaries are expected by mid-September

Reverse stock split successfully executed

August 20, 2026

BERKELEY, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies, previously announced the signing of an Option Agreement (the Agreement) which provides Profusa the... More